Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric intravenous vedolizumab dose-ranging study in ulcerative colitis or Crohn's disease
NL-OMON46400Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vedolizumab in autoimmune colitis and Crohn's disease (4 arms), sponsored by Takeda. Primary endpoints: Area under the serum concentration-time curve at Week 14, Average serum concentration during a dosing interval at Week 14 and 1 more. Planned start Sep 2017; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON46400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46400.